Trial Profile
Phase II study of nivolumab plus gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma -HN17-11
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms NPC
- Sponsors Ono Pharmaceutical
- 12 Jul 2022 Status changed from recruiting to completed, according to Results published in the Clinical Cancer Research.
- 12 Jul 2022 Results published in the Clinical Cancer Research
- 15 Nov 2018 New trial record